

Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

Information for the public

Published: 7 May 2026

www.nice.org.uk

Zanidatamab (Ziihera) is available on the NHS. It is a possible treatment for HER2-positive (immunohistochemistry 3 positive) unresectable locally advanced or metastatic biliary tract cancer in adults after at least 1 line of systemic treatment.

Locally advanced means the cancer has spread to nearby tissues. Unresectable means it cannot be removed with surgery.

Lines of treatment are a sequence of treatments, starting with the most suitable and moving to alternatives if the first does not work or the condition gets worse. Each line can be a single drug or a combination of drugs.

Systemic treatments are medicines that work throughout the whole body.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on bile duct cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [AMMF – The Cholangiocarcinoma Charity](#), 01279 662 479
- [Cancer Research UK](#), 0800 00 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9456-4